Adding suicide prevention to the triple advantages of injectable long-acting second-generation antipsychotics
Recently, Stahl challenged out the traditional association between LAI formulations of antipsychotics and patients with schizophrenia with the most severe symptoms, in addition to those with the poorest adherence to treatment, numerous hospitalizations, and chronicity of the disorder. Antipsychotics and mortality in a nationwide cohort of 29, 823 patients with schizophrenia.